AxoGen, Inc. (AXGN) P/E Ratio History
Deep ValueTrading at -131.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1991–2010
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, AxoGen, Inc. (AXGN) trades at a price-to-earnings ratio of -131.5x, with a stock price of $44.72 and trailing twelve-month earnings per share of $-0.61.
The current P/E is 348% below its 5-year average of 53.0x. Over the past five years, AXGN's P/E has ranged from a low of 0.3x to a high of 305.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, AXGN trades at a 674% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, AXGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AXGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AXGN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AXGN P/E vs Peers
Neuromodulation and neuro devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $60M | 14.2 | - | +125% | |
| $581M | 12.2Lowest | - | +14% | |
| $8B | 159.3 | - | +287%Best | |
| $144B | 51.6 | 2.37Best | +23% | |
| $127B | 39.3 | 2.65 | +8% | |
| $18B | 25.7 | - | -20% | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AXGN Historical P/E Data (1991–2010)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2010 Q3 | - | $3.50 | $3.03 | 1.2x | -98% |
| FY2010 Q2 | Jun 30 2010 | $2.99 | $3.39 | 0.9x | -98% |
| FY2010 Q1 | Mar 31 2010 | $3.10 | $3.47 | 0.9x | -98% |
| FY2009 Q4 | - | $4.02 | $3.50 | 1.1x | -98% |
| FY2006 Q1 | Mar 31 2006 | $0.58 | $0.00 | 305.3x | +551% |
| FY2005 Q3 | Sep 30 2005 | $0.75 | $0.09 | 8.3x | -82% |
| FY2005 Q2 | - | $1.50 | $0.37 | 4.1x | -91% |
| FY2005 Q1 | - | $2.00 | $0.40 | 5.1x | -89% |
| FY2004 Q4 | Dec 31 2004 | $1.50 | $0.56 | 2.7x | -94% |
| FY2004 Q3 | - | $1.35 | $0.27 | 5.0x | -89% |
| FY2002 Q2 | Jun 30 2002 | $0.80 | $2.63 | 0.3x | -99% |
| FY2002 Q1 | Mar 31 2002 | $1.20 | $2.68 | 0.4x | -99% |
| FY2001 Q3 | Sep 30 2001 | $1.80 | $3.69 | 0.5x | -99% |
| FY2001 Q2 | Jun 30 2001 | $2.25 | $3.68 | 0.6x | -99% |
| FY2001 Q1 | Mar 31 2001 | $1.75 | $0.31 | 5.6x | -88% |
| FY2000 Q4 | Dec 31 2000 | $1.88 | $0.28 | 6.7x | -86% |
| FY1995 Q2 | Jun 30 1995 | $11.75 | $0.05 | 235.0x | +401% |
| FY1995 Q1 | Mar 31 1995 | $11.00 | $0.07 | 157.1x | +235% |
| FY1994 Q4 | Dec 31 1994 | $7.25 | $0.03 | 241.7x | +415% |
| FY1994 Q3 | Sep 30 1994 | $7.00 | $0.09 | 77.8x | +66% |
| FY1994 Q2 | - | $8.33 | $0.17 | 49.0x | +4% |
| FY1994 Q1 | - | $9.05 | $0.23 | 39.3x | -16% |
| FY1993 Q4 | Dec 31 1993 | $10.00 | $0.28 | 35.7x | -24% |
| FY1993 Q3 | - | $10.71 | $0.23 | 46.6x | -1% |
| FY1993 Q2 | Jun 30 1993 | $8.62 | $0.20 | 43.1x | -8% |
| FY1993 Q1 | Mar 31 1993 | $10.88 | $0.22 | 49.5x | +5% |
| FY1992 Q4 | - | $10.20 | $0.24 | 42.5x | -9% |
| FY1992 Q3 | Sep 30 1992 | $9.75 | $0.30 | 32.5x | -31% |
| FY1992 Q2 | - | $7.13 | $0.31 | 23.0x | -51% |
| FY1992 Q1 | - | $8.85 | $0.29 | 30.2x | -36% |
| FY1991 Q4 | - | $9.61 | $0.29 | 32.8x | -30% |
| FY1991 Q3 | Sep 30 1991 | $11.01 | $0.29 | 37.6x | -20% |
| FY1991 Q2 | Jun 30 1991 | $7.34 | $0.28 | 25.9x | -45% |
Average P/E for displayed period: 46.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
35+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AXGN — Frequently Asked Questions
Quick answers to the most common questions about buying AXGN stock.
What is AXGN's P/E ratio?
AxoGen, Inc. (AXGN) trailing twelve-month P/E ratio is -131.5x, based on TTM diluted EPS of $-0.61. The 5-year average P/E is 53.0x and the historical range spans 0.3x to 305.3x.
Is AXGN stock overvalued or undervalued?
AXGN trades at -131.5x P/E, below its 5-year average of 53.0x. At the 0th percentile of its historical range (0.3x–305.3x), the stock is priced at a discount to its own history.
Is AXGN stock expensive?
No, AXGN is not expensive on a historical basis. The current P/E of -131.5x is below the 5-year average of 53.0x and sits at the 0th percentile of its valuation range.
What is AXGN's historical P/E range?
Over the past 5 years, AXGN's P/E ratio has ranged from 0.3x to 305.3x, with a median of 5.0x and an average of 53.0x. The current P/E of -131.5x places the stock at the 0th percentile of this range. Full historical data spans 1991–2010.
How does AXGN's P/E compare to the S&P 500?
AXGN trades at -131.5x P/E versus the S&P 500 median of 25.1x. The 624% discount to the market suggests lower growth expectations or perceived higher risk.
How does AXGN's valuation compare to Healthcare peers?
AxoGen, Inc. P/E of -131.5x compares to the Healthcare sector median of 22.9x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AXGN's PEG ratio?
AXGN PEG ratio is N/A, based on a P/E of -131.5x and EPS growth of -47.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AXGN's earnings yield?
AXGN earnings yield is N/A, the inverse of its -131.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.